Phase 3 Readout
CGON: Phase 3 Topline: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prosta
November 11, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- November 11, 2026
- Company
- CG Oncology, Inc. (CGON)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prosta
- Company
- CG Oncology, Inc. (CGON)
- Indication
- Prostate Adenocarcinoma